San Diego biotech raises $77.5M to target proteins with therapeutic potential

Back to Team

San Diego’s Escient Pharmaceuticals announced Monday that it has raised $77.5 million for research the company believes could lead to new treatments for certain kidney and liver disorders, among other diseases.

The biotech has zeroed in on a group of proteins called G-protein coupled receptors. We have more than 700 such proteins, which regulate everything from smell and taste to the signals that make neurons fire in the brain. Many of these proteins can be targeted by existing drugs, but 150 of them continue to stump scientists.